Chinese Journal of Dermatology ›› 2018, Vol. 51 ›› Issue (11): 849-852.doi: 10.3760/cma.j.issn.0412-4030.2018.11.027
Liu Wei, Liu Jiawei, Qian Yuetong, Ma Donglai
Received:2017-11-07
Revised:2018-02-01
Online:2018-11-16
Published:2018-10-31
Contact:
Ma Donglai
E-mail:mdonglai@sohu.com
Liu Wei, Liu Jiawei, Qian Yuetong, Ma Donglai. Drug treatment of vitiligo: an update[J].Chinese Journal of Dermatology, 2018, 51(11): 849-852.
| ［1］ | Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo［J］. Lancet, 2015,386（9988）:74⁃84. doi: 10.1016/S0140⁃6736（14）60763⁃7.<br /> |
| ［2］ | Minder EI, Barman⁃Aksoezen J, Schneider⁃Yin X. Pharmacoki⁃netics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders［J］. Clin Pharmacokinet, 2017,56（8）:815⁃823. doi: 10.1007/s40262⁃016⁃0501⁃5.<br /> |
| ［3］ | Grimes PE, Hamzavi I, Lebwohl M, et al. The efficacy of afamelanotide and narrowband UV⁃B phototherapy for repigmen⁃tation of vitiligo［J］. JAMA Dermatol, 2013,149（1）:68⁃73. doi: 10.1001/2013.jamadermatol.386.<br /> |
| ［4］ | Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV⁃B phototherapy for the treatment of vitiligo: a randomized multicenter trial［J］. JAMA Dermatol, 2015,151（1）:42⁃50. doi: 10.1001/jamadermatol.2014.1875.<br /> |
| ［5］ | Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo［J］. J Am Acad Dermatol, 2017,77（1）:17⁃29. doi: 10.1016/j.jaad.2016.11.010.<br /> |
| ［6］ | Dillon AB, Sideris A, Hadi A, et al. Advances in vitiligo: an update on medical and surgical treatments［J］. J Clin Aesthet Dermatol, 2017,10（1）:15⁃28.<br /> |
| ［7］ | Passeron T. Indications and limitations of afamelanotide for treating vitiligo［J］. JAMA Dermatol, 2015,151（3）:349⁃350. doi: 10.1001/jamadermatol.2014.4848.<br /> |
| ［8］ | Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo［J］. Sci Transl Med, 2014,6（223）:223ra23. doi: 10.1126/scitranslmed.3007811.<br /> |
| ［9］ | Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.<br /> |
| ［10］ | Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmen⁃tation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.<br /> |
| ［11］ | Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060. doi: 10.1016/j.jaad.2017.02. 049.<br /> |
| ［12］ | Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomi⁃tant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682. doi: 10.1016/j.jaad.2017.05.043.<br /> |
| ［13］ | Scott G, Jacobs S, Leopardi S, et al. Effects of PGF2alpha on human melanocytes and regulation of the FP receptor by ultraviolet radiation［J］. Exp Cell Res, 2005,304（2）:407⁃416. doi: 10.1016/j.yexcr.2004.11.016.<br /> |
| ［14］ | Scott G, Leopardi S, Printup S, et al. Proteinase⁃activated receptor⁃2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity［J］. J Invest Dermatol, 2004,122（5）:1214⁃1224.<br /> |
| ［15］ | Anbar TS, El⁃Ammawi TS, Abdel⁃Rahman AT, et al. The effect of latanoprost on vitiligo: a preliminary comparative study［J］. Int J Dermatol, 2015,54（5）:587⁃93. doi: 10.1111/ijd.12631.<br /> |
| ［16］ | Korobko IV, Lomonosov KM. A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow⁃band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo［J］. Dermatol Ther, 2016,29（6）:437⁃441. doi: 10.1111/dth.12383.<br /> |
| ［17］ | Stanimirovic A, Kovacevic M, Korobko I, et al. Combined therapy for resistant vitiligo lesions: NB⁃UVB, microneedling, and topical latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB⁃UVB［J］. Dermatol Ther, 2016,29（5）:312⁃316. doi: 10.1111/dth.12363.<br /> |
| ［18］ | Jha AK, Sinha R, Prasad S, et al. Bimatoprost in periorbital vitiligo: a ray of hope or dilemma［J］. J Eur Acad Dermatol Venereol, 2016,30（7）:1247⁃1248. doi: 10.1111/jdv.13176.<br /> |
| ［19］ | Webb KC, Tung R, Winterfield LS, et al. Tumour necrosis factor⁃α inhibition can stabilize disease in progressive vitiligo［J］. Br J Dermatol, 2015,173（3）:641⁃650. doi: 10.1111/bjd.14016.<br /> |
| ［20］ | Carvalho CL, Ortigosa LC. Segmental vitiligo after infliximab use for rheumatoid arthritis⁃⁃a case report［J］. An Bras Dermatol, 2014,89（1）:154⁃156. doi: 10.1590/abd1806⁃4841.20142887.<br /> |
| ［21］ | Alghamdi KM, Khurrum H, Taieb A, et al. Treatment of generalized vitiligo with anti⁃TNF⁃α agents［J］. J Drugs Dermatol, 2012,11（4）:534⁃539.<br /> |
| ［22］ | Rigopoulos D, Gregoriou S, Larios G, et al. Etanercept in the treatment of vitiligo［J］. Dermatology, 2007,215（1）:84⁃85. doi: 10.1159/000102044.<br /> |
| ［23］ | Campanati A, Giuliodori K, Ganzetti G, et al. A patient with psoriasis and vitiligo treated with etanercept［J］. Am J Clin Dermatol, 2010,11（ Suppl 1）:46⁃48. doi: 10.2165/1153424⁃S0⁃000000000⁃00000.<br /> |
| ［24］ | Maruthappu T, Leandro M, Morris SD. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab［J］. Dermatol Ther, 2013,26（4）:370⁃372. doi: 10.1111/ dth.12002.<br /> |
| ［25］ | Iannella G, Greco A, Didona D, et al. Vitiligo: pathogenesis, clinical variants and treatment approaches［J］. Autoimmun Rev, 2016,15（4）:335⁃343. doi: 10.1016/j.autrev.2015.12.006.<br /> |
| ［26］ | Chang Y, Li S, Guo W, et al. Simvastatin protects human melanocytes from H2O2⁃induced oxidative stress by activating nrf2［J］. J Invest Dermatol, 2017,137（6）:1286⁃1296. doi: 10.1016/j.jid.2017.01.020.<br /> |
| ［27］ | Zhao Y, Gartner U, Smith FJ, et al. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita［J］. J Invest Dermatol, 2011,131（5）:1045⁃1052. doi: 10.1038/jid.2011.41.<br /> |
| ［28］ | Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo［J］. J Invest Dermatol, 2015,135（4）:1080⁃1088. doi: 10.1038/jid.2014.529.<br /> |
| ［29］ | Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG⁃CoA reductase inhibitor on vitiligo［J］. Lipids Health Dis, 2004,3（1）:7. doi: 10.1186/1476⁃511X⁃3⁃7.<br /> |
| ［30］ | Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃II clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151. doi: 10.1016/j.jaad.2016.06.015.<br /> |
| ［31］ | Iraji F, Banihashemi SH, Faghihi G, et al. A Comparison of betamethasone valerate 0.1 cream twice daily plus oral simvastatin versus betamethasone valerate 0.1 cream alone in the treatment of vitiligo patients［J］. Adv Biomed Res, 2017,6:34. doi: 10.4103/2277⁃9175.203159.<br /> |
| ［32］ | Jimenez⁃Brito G, Garza⁃de⁃La⁃Peña E, Pérez⁃Romano B, et al. Serum antibodies to melanocytes in patients with vitiligo are predictors of disease progression［J］. Skinmed, 2016,14（1）:17⁃21.<br /> |
| ［33］ | Ruiz⁃Argüelles A, García⁃Carrasco M, Jimenez⁃Brito G, et al. Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study［J］. Clin Exp Immunol, 2013,174（2）:229⁃236. doi: 10.1111/cei.12168.<br /> |
| No related articles found! |
|
